Home Alzheimer’s Disease Planned Clinical Trial of Low Dose Selinexor in Patients with Severe COVID-19

Planned Clinical Trial of Low Dose Selinexor in Patients with Severe COVID-19

Karyopharm Therapeutics announced plans to begin a global randomized clinical trial for low dose oral selinexor (Xpovio) in hospitalized patients with severe coronavirus disease 2019 (COVID-19). 

Currently, selinexor, a selective inhibitor of nuclear export compound which blocks the cellular protein XP01, is approved at higher doses by the FDA as a treatment for patients with relapsed or refractory multiple myeloma.

As of now, selinexor is the only XPO1 inhibitor approved by the FDA for commercial use and has been extensively tested in clinical trials across numerous cancer indications globally since 2012. The proposed clinical trial treating hospitalized patients with COVID-19 would be the first study of an XPO1 inhibitor in patients with severe viral infections. 

“While Karyopharm’s clinical development strategy until now has been focused on patients with various types of…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

32 year old singer Tom Parker of The Wanted diagnosed with stage 4 glioblastoma

submitted by /u/Jexlan Continue Reading to the Source

Recent Comments